IRIS Accounts Production v24.3.0.553 12700360 Board of Directors Board of Directors 1.4.23 31.3.24 31.3.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh127003602023-03-31127003602024-03-31127003602023-04-012024-03-31127003602022-03-31127003602022-04-012023-03-31127003602023-03-3112700360ns15:EnglandWales2023-04-012024-03-3112700360ns14:PoundSterling2023-04-012024-03-3112700360ns10:Director12023-04-012024-03-3112700360ns10:Director22023-04-012024-03-3112700360ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3112700360ns10:SmallEntities2023-04-012024-03-3112700360ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3112700360ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3112700360ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3112700360ns10:FullAccounts2023-04-012024-03-3112700360ns10:Director42023-04-012024-03-3112700360ns10:CompanySecretary12023-04-012024-03-3112700360ns10:RegisteredOffice2023-04-012024-03-3112700360ns5:CurrentFinancialInstruments2024-03-3112700360ns5:CurrentFinancialInstruments2023-03-3112700360ns5:Non-currentFinancialInstruments2024-03-3112700360ns5:Non-currentFinancialInstruments2023-03-3112700360ns5:ShareCapital2024-03-3112700360ns5:ShareCapital2023-03-3112700360ns5:SharePremium2024-03-3112700360ns5:SharePremium2023-03-3112700360ns5:RetainedEarningsAccumulatedLosses2024-03-3112700360ns5:RetainedEarningsAccumulatedLosses2023-03-3112700360ns5:LandBuildings2023-03-3112700360ns5:PlantMachinery2023-03-3112700360ns5:LandBuildings2023-04-012024-03-3112700360ns5:PlantMachinery2023-04-012024-03-3112700360ns5:LandBuildings2024-03-3112700360ns5:PlantMachinery2024-03-3112700360ns5:LandBuildings2023-03-3112700360ns5:PlantMachinery2023-03-3112700360ns5:CostValuation2023-03-3112700360ns5:AdditionsToInvestments2024-03-3112700360ns5:CostValuation2024-03-3112700360ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3112700360ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-31
REGISTERED NUMBER: 12700360 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2024

for

Virus Shield Biosciences Limited

Virus Shield Biosciences Limited (Registered number: 12700360)






Contents of the Financial Statements
for the Year Ended 31 March 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Virus Shield Biosciences Limited

Company Information
for the Year Ended 31 March 2024







DIRECTORS: Mrs J Shaw
C A Shaw
DF Haller JR





SECRETARY: Mrs J Shaw





REGISTERED OFFICE: Unit 2 Charlton Business Park
Westfield Industrial Estate
Radstock
Somerset
BA3 4BE





REGISTERED NUMBER: 12700360 (England and Wales)





ACCOUNTANTS: Edward Howells Associates Limited
Chartered Certified Accountants
20a High Street
Glastonbury
Somerset
BA6 9DU

Virus Shield Biosciences Limited (Registered number: 12700360)

Balance Sheet
31 March 2024

31.3.24 31.3.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 42,270 58,638
Investments 5 3,294 3
45,564 58,641

CURRENT ASSETS
Stocks 142,197 189,796
Debtors 6 1,525,827 768,167
Cash at bank and in hand 159,268 72,089
1,827,292 1,030,052
CREDITORS
Amounts falling due within one year 7 764,481 303,828
NET CURRENT ASSETS 1,062,811 726,224
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,108,375

784,865

CREDITORS
Amounts falling due after more than one
year

8

1,499,905

-
NET (LIABILITIES)/ASSETS (391,530 ) 784,865

CAPITAL AND RESERVES
Called up share capital 100 100
Share premium 1,685,453 1,685,453
Retained earnings (2,077,083 ) (900,688 )
(391,530 ) 784,865

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Virus Shield Biosciences Limited (Registered number: 12700360)

Balance Sheet - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 18 November 2024 and were signed on its behalf by:




Mrs J Shaw - Director



C A Shaw - Director


Virus Shield Biosciences Limited (Registered number: 12700360)

Notes to the Financial Statements
for the Year Ended 31 March 2024

1. STATUTORY INFORMATION

Virus Shield Biosciences Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about Virus Shield Biosciences Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Virus Shield Biosciences Limited (Registered number: 12700360)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

2. ACCOUNTING POLICIES - continued

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 7 (2023 - 7 ) .

4. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
COST
At 1 April 2023 29,164 49,649 78,813
Additions 5,625 18,344 23,969
Disposals (29,164 ) (11,995 ) (41,159 )
At 31 March 2024 5,625 55,998 61,623
DEPRECIATION
At 1 April 2023 6,905 13,270 20,175
Charge for year 234 7,599 7,833
Eliminated on disposal (6,906 ) (1,749 ) (8,655 )
At 31 March 2024 233 19,120 19,353
NET BOOK VALUE
At 31 March 2024 5,392 36,878 42,270
At 31 March 2023 22,259 36,379 58,638

5. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 April 2023 3
Additions 3,291
At 31 March 2024 3,294
NET BOOK VALUE
At 31 March 2024 3,294
At 31 March 2023 3

Virus Shield Biosciences Limited (Registered number: 12700360)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade debtors 133,753 7,016
Amounts owed by group undertakings 1,221,719 666,501
Other debtors 170,355 94,650
1,525,827 768,167

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Bank loans and overdrafts 1,687 345
Trade creditors 80,675 15,329
Taxation and social security 7,651 6,135
Other creditors 674,468 282,019
764,481 303,828

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.3.24 31.3.23
£    £   
Bank loans 1,499,905 -